AI: The Next Revolution In Medicine?

Jan 23, 2019

AI: The Next Revolution In Medicine?

Tagged:

Watch our CEO, Joanna Shields, as she takes the stage and returns to DLD 2019 - an event which is a source of great inspiration and hope.

Given the state of the world today, at BenevolentAI we think we could all benefit from a giant dose of optimism. We believe that unconventional thinking combined with purposeful technology can truly change outcomes in the world. And that is what Joanna touches upon during her talk to the audience at DLD.

More Posts

You Might Also Like

Interim results for the six months ended 30 June 2022

Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.

Sep 27, 2022

Analyst / Investor Event

BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.

Sep 27, 2022

Building the data foundations to accelerate drug discovery

Mark Davies, BenevolentAI’s SVP Informatics and Data, discusses innovations that enable BenevolentAI to leverage biomedical data in drug discovery.

Sep 22, 2022

Analyst / Investor Event and Interim Results

BenevolentAI is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 – 17:00 BST (09:00 – 12:00 ET) on Tuesday, 27 September 2022.

Sep 16, 2022

Text & Data Mining in Drug Discovery: A Conversation with Springer Nature

Hear Mark Davies, SVP Informatics and Data, speak to Springer Nature about how BenevolentAI is leveraging the scientific literature to expedite drug discovery.

Sep 2, 2022

Notice of Interim Results and Analyst / Investor Event

BenevolentAI will announce interim results on the 27th of September and hold an analyst and investor event on the same day. Find out more.

Aug 26, 2022